ERBB2 (HER2) Testing in Breast Cancer

被引:5
|
作者
Hilal, Talal [1 ]
Romond, Edward H. [2 ]
机构
[1] Univ Kentucky, Dept Internal Med, Lexington, KY 40536 USA
[2] Univ Kentucky, Markey Canc Ctr, Div Med Oncol, Lexington, KY 40536 USA
来源
关键词
NCCTG N9831; SURVIVAL;
D O I
10.1001/jama.2015.17463
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:1280 / 1281
页数:2
相关论文
共 50 条
  • [1] Treatment options in ErbB2 (HER2)-overexpressing breast cancer
    Jackisch, Christian
    BREAST CARE, 2008, 3 : 1 - 1
  • [2] Challenges in the treatment of ErbB2 (HER2)-positiive breast cancer
    Jackisch, Christian
    EJC SUPPLEMENTS, 2008, 6 (05): : 7 - 14
  • [3] HER2/ERBB2 Testing in Breast Carcinoma by Next Generation Sequencing
    Wong, Adele
    Bhan, Atul
    Lennerz, Jochen K.
    Brachtel, Elena
    MODERN PATHOLOGY, 2017, 30 : 522A - 522A
  • [4] HER2/ERBB2 Testing in Breast Carcinoma by Next Generation Sequencing
    Wong, Adele
    Bhan, Atul
    Lennerz, Jochen K.
    Brachtel, Elena
    LABORATORY INVESTIGATION, 2017, 97 : 522A - 522A
  • [5] Molecular mechanisms underlying ErbB2/HER2 action in breast cancer
    Harari, D
    Yarden, Y
    ONCOGENE, 2000, 19 (53) : 6102 - 6114
  • [6] Molecular mechanisms underlying ErbB2/HER2 action in breast cancer
    Daniel Harari
    Yosef Yarden
    Oncogene, 2000, 19 : 6102 - 6114
  • [7] Future options in the treatment of ErbB2 (HER2)-positive breast cancer
    Fumoleau, Pierre
    EJC SUPPLEMENTS, 2008, 6 (05): : 25 - 31
  • [8] Tucatinib HER2 (ErbB2) inhibitor Treatment of breast and colorectal cancer
    Patil, T.
    Shagisultanova, E.
    Borges, V. F.
    DRUGS OF THE FUTURE, 2019, 44 (01) : 11 - 19
  • [9] COMPLETE - Study the ErbB2 (HER2) - positive Breast cancer.
    Arnheim, Katharina
    Aktas, Bahriye
    ONKOLOGIE, 2010, 33 (04):
  • [10] ErbB2 (HER2)-positives MammakarzinomResistenzmechanismenErbB2 (HER2) positive breast cancer Mechanisms of resistance
    K. Kast
    W. Distler
    Der Gynäkologe, 2010, 43 (7): : 574 - 578